ESR1 and breast cancer: In the cohort study, high expression of LIAS, FDX1, LIPT1, DLD, PDH1, and ATP7B, coupled with low CDKN2A expression, was associated with favorable RFS in patients with estrogen receptor-positive early breast cancer (ER+ EBC).